Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for steroid-resistant central diabetes insipidus associated with lymphocytic hypophysitis
jRCTs041260025Recruiting
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of abatacept in Lymphocytic hypophysitis (LYH) and arginine vasopressin deficiency (CDI). Primary endpoint: Change in pituitary and pituitary stalk mass lesions on MRI. Started Oct 2026; status: recruiting.
02
Drugs
abatacept
03
Conditions
Lymphocytic hypophysitis (LYH)arginine vasopressin deficiency (CDI)
Beyond the preview
Go deeper on jRCTs041260025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260025.